Yesterday it was reported that the VP, Strategic Bus. Initiatives of Arrowhead Research (NASDAQ: ARWR), Peter Brian Leone, exercised options to sell 131,137 ARWR shares at $6.19 a share, for a total transaction value of $1.77M.
See today’s analyst top recommended stocks >>
Currently, Arrowhead Research has an average volume of 1.45M. The Company has a Price to Book ratio of 11.1284.
Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $22.50, reflecting a 73.6% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arrowhead Pharmaceuticals, Inc. engages as a biopharmaceutical company developing targeted RNAi therapeutics. Its pipeline includes clinical programs in chronic hepatitis B virus and partner based programs in obesity and oncology. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Read More on ARWR:
